Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C15H15N3O3
|
| gptkbp:clinicalTrials |
Phase III trials
|
| gptkbp:compatibleWith |
approximately 50%
|
| gptkbp:contraindication |
severe renal impairment
active peptic ulcer hypersensitivity to NSAIDs |
| gptkbp:developedBy |
gptkb:Bausch_+_Lomb
|
| gptkbp:drugInterdiction |
NSAID
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nepafenac
|
| gptkbp:isATypeOf |
70458-96-7
|
| gptkbp:issuedBy |
eye drops
|
| gptkbp:lastProduced |
2005
|
| gptkbp:marketedAs |
Ilevro
Nevanac |
| gptkbp:operates_in |
S01BC07
|
| gptkbp:route |
topical
|
| gptkbp:sideEffect |
blurred vision
eye irritation burning sensation dry eye |
| gptkbp:triggerType |
COX_inhibitor
|
| gptkbp:usedFor |
treatment of inflammation
treatment of pain |